TREATMENT OF THE NON-SMALL CELL BRONCHIAL-CARCINOMA WITH CIS-PLATINUM, IFOSFAMIDE, VINDESINE AND VP 16
- 1 January 1985
- journal article
- research article
- Vol. 161 (3) , 131-133
Abstract
Hitherto, the objective of chemotherapy in case of the non-small cell bronchial carcinoma is only of a palliative nature. Thus a critical indication is necessary. This is confirmed by investigations with the combinations of cis-platinum and ifosfamide (80 patients, remission rate 35%, median survival time of patients with remission 11.5 mo.), cis-platinum and vindesine (29 patients, remission rate 28%, median survival time of patients with remission 14.5 mo. and ifosfamide and vepeside (63 patients, remission rate 27%, median survival time of patients with remissin 12 mo.). The combination ifosfamide-vepeside was much better tolerated by the patients and, with its comparable remission rates and survival times, was superior to the cis-platinum combinations. For the chemotherapy and the non-small cell bronchial carcinoma it has to be considered that the treatment result may be more influenced by tumor stage and activity index of the parent than by the therapy method.This publication has 2 references indexed in Scilit:
- Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium)Cancer, 1982
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage SchedulesAnnals of Internal Medicine, 1981